Cancer immunotherapy by fusions of dendritic cells and tumor cells

Immunotherapy

Volumn 1, Issue 1, 2009, Pages 49-62

  Koido, Shigeo ^a   Hara, Eiichi ^b   Homma, Sadamu ^a   Ohkusa, Toshifumi ^a   Gong, Jianlin ^c   Tajiri, Hisao ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAITAMA CANCER CENTER   (Japan)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer vaccine; CD4+ T cell; CD8+ T cell; Dendritic cell; Dendritic tumor fusion cell; Tumor associated antigen

Indexed keywords

B7 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CD86 ANTIGEN; DENDRITIC CELL TUMOR FUSION CELL VACCINE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MUCIN 1; PICIBANIL; RECOMBINANT INTERLEUKIN 12; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; WT1 PROTEIN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; BREAST CANCER; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUSION; COLORECTAL CANCER; COLORECTAL CARCINOMA; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GLIOMA; HUMAN; IMMUNOGENICITY; KIDNEY CARCINOMA; MELANOMA; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; STOMACH CANCER; T LYMPHOCYTE ACTIVATION; TUMOR CELL;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL DIFFERENTIATION; CELL FUSION; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TUMOR CELLS, CULTURED;

EID: 77749287801     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/1750743X.1.1.49     Document Type: Review

References (124)

1. Steinman RM: The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9, 271-296 (1991). ■■ Very through review of the phenotype and function of dendritic cells (DCs).
2. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 392(6673), 245-252 (1998). ■■ Outstanding review of the immune system and how to regulate tumor immunity or tolerance induction by DCs.
3. Berard F, Blanco P, Davoust J et al.: Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J. Exp. Med. 192(11), 1535-1544 (2000).
4. Thurner B, Haendle I, Roder C et al.: Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190(11), 1669-1678 (1999).
5. + hematopoietic progenitor cells. Int. J. Cancer. 86(3), 385-392 (2000).
6. Mayordomo JI, Zorina T, Storkus WJ et al.: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1(12), 1297-1302 (1995).
7. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr: Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 183(1), 283-287 (1996).
8. Nestle FO, Alijagic S, Gilliet M et al.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4(3), 328-332 (1998).
9. Strobel I, Berchtold S, Gotze A et al.: Human dendritic cells transfected with either RNA or DNA encoding influzenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes. Gene Ther. 7(23), 2028-2035 (2000). (Pubitemid 32036769)
10. Koido S, Kashiwaba M, Chen D et al.: Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J. Immunol. 165(10), 5713-5719 (2000). (Pubitemid 30836183)
11. Gong J, Chen D, Kashiwaba M, Kufe D: Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. 3(5), 558-561 (1997). ■ First publication that provides proof of principle of DC/tumor fusion vaccine.
12. Gong J, Koido S, Calderwood SK: Cell fusion: from hybridoma to dendritic cell-based vaccine. Expert Rev. Vaccines 7(7), 1055-1068 (2008).
13. Gong J, Chen D, Kashiwaba M et al.: Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc. Natl Acad. Sci. USA 95(11), 6279-6283 (1998).
14. Gong J, Koido S, Chen D et al.: Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood 99(7), 2512-2517 (2000). (Pubitemid 34525439)
15. Koido S, Tanaka Y, Chen D, Kufe D, Gong J: The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice. J. Immunol. 168(5), 2111-2117 (2002). (Pubitemid 34171809)
16. Tanaka Y, Koido S, Chen D et al.: Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice. Clin. Immunol. 101(2), 192-200 (2001).
17. Xia J, Tanaka Y, Koido S et al.: Prevention of spontaneous breast carcinoma by prophylatic vaccination with dendritic/tumor fusion cells. J. Immunol. 170(4), 1980-1986 (2003).
18. Inaba K, Witmer-Pack M, Inaba M et al.: The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J. Exp. Med. 180(5), 1849-1860 (1994).
19. Young JW, Inaba K: Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J. Exp. Med. 183(1), 7-11 (1996).
20. Inaba K, Pack M, Inaba M et al.: High levels of a major histocompatibility complex II - self peptide complex on dendritic cells from the T cell areas of lymph nodes. J. Exp. Med. 186(5), 665-672 (1997).
21. Wang J, Saffold S, Cao X, Krauss J, Chen W: Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J. Immunol. 161(10), 5516-5524 (1998). (Pubitemid 28519115)
22. Cao X, Zhang W, Wang J et al.: Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells. Immunology 97(4), 616-625 (1999). (Pubitemid 29356411)
23. Tanaka H, Shimizu K, Hayashi T, Shu S: Therapeutic immune response induced by electrofusion of dendritic and tumor cells. Cell. Immunol. 220(1), 1-12 (2002).
24. Li J, Holmes LM, Franek KJ et al.: Purified hybrid cells from dendritic cell and tumor cell fusions are superior activators of antitumor immunity Cancer Immunol. Immunother. 50(9), 456-462 (2001). (Pubitemid 33079341)
25. Shimizu K, kuriyama H, Kjaergaard J et al.: Comparative analysisi of antigen loading strategies of dendritic cells for tumor immunotherapy. J. Immunother. 27(4), 265-272 (2004). ■ Reports that DC/tumor fusion cells are far superior to other DC-based vaccines.
26. Hiraoka K, Yamamoto S, Otsuru S et al.: Enhanced tumor-specific long-term immunity of hemagglutinating (correction of hemaggluttinating) virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides. J. Immunol. 173(7), 4297-4307 (2004). (Pubitemid 39280657)
27. Phan V, Errington F, Cheong SC et al.: A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines. Nat. Med. 9(9), 1215-1219 (2003).
28. Suzuki T, Fukuhara T, Tanaka M et al.: Vaccination of dendritic cells loaded with interleukin-12 secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells. Clin. Cancer Res. 11(1), 58-66 (2005).
29. Kao JY, Gong Y, Chen CM, Zheng QD, Chen JJ: Tumor-derived TGF-β reduces the efficacy of dendritic cell/tumor fusion vaccine. J. Immunol. 170(7), 3806-3811 (2003). (Pubitemid 36359250)
30. Yasuda T, Kamigaki T, Kawasaki K et al.: Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma. Cancer Immunol. Immunother. 56(7), 1025-1036 (2007).
31. Homma S, Toda G, Gong J, Kufe D, Ohno T: Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice. J. Gastroenterol. 36(11), 764-771 (2001). (Pubitemid 33133502)
32. Zhang HM, Zhang LW, Liu WC et al.: Comparative analysis of DC fused with tumor cells or transfected with tumor total RNA as potential cancer vaccines against hepatocellular carcinoma. Cytotherapy 8(6), 580-588 (2006).
33. Liu Y, Zhang W, Chan T, Saxena A, Xiang J: Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity. Leuk. Res. 26(8), 757-763 (2002).
34. Ceiluzzi CM, Falo LDJ: Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J. Immunol. 160(7), 3081-3085 (1998).
35. Lespagnard L, Mettens P, Verheyden AM et al.: Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor immunity. Int. J. Cancer. 76(2), 250-258 (1998).
36. Tamai H, Watanabe S, Zheng R et al.: Effective treatment of spontaneous metastases derived from a poorly immunogenic murine mammary carcinoma by combined dendritic-tumor hybrid vaccination and adoptive transfer of sensitized T cells. Clin. Immunol. 127(1), 66-77 (2008).
37. Siders WM, Vergilis KL, Johnson C, Shields J, Kaplan JM: Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells. Mol. Ther. 7(4), 498-505 (2003).
38. Kjaergaard J, Shimizu K, Shu S: Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine. Cell. Immunol. 225(2), 65-74 (2003).
39. Kufe D, Inghirami G, Abe M et al.: Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 3(3), 223-232 (1984). (Pubitemid 15184701)
40. Patton S, Gendler SJ, Spicer AP: The epithelial mucin, MUC1, of milk, mammary gland and other tissues. Biochim. Biophys. Acta. 1241(3), 407-423 (1995).
41. Gong J, Chen L, Chen D et al.: Induction of antigen-specific antitumor immunity with adenovirus-transduced dendritic cells. Gene Ther. 4(10), 1023-1028 (1997). (Pubitemid 27469931)
42. Gong J, Nikrui N, Chen D et al.: Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J. Immunol. 165(3), 1705-1711 (2000). (Pubitemid 30604610)
43. Koido S, Nikrui N, Ohana M et al.: Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use. Gynecol. Oncol. 99(2), 462-471 (2005).
44. Koido S, Hara E, Torii A et al.: Induction of antigen-specific CD4 and CD8 mediated T cell responses by fusion of autologous dendritic cells and metastatic colorectal cancer cells. Int. J. Cancer. 117(4), 587-595 (2005).
45. Rowse GJ, Tempera RM, VanLith ML, Hollingsworth MA, Gendler SJ: Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res. 58(2), 315-321 (1998).
46. Guy CT, Cardiff RD, Muller WJ: Induction of mammary tumors by expression of Polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol. Ther. Cell Biol. 12(3), 954-961 (1992).
47. Gong J, Koido S, Kato Y et al.: Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts. Leuk. Res. 28(12), 1303-1312 (2004).
48. Gong J, Avigan D, Chen D et al.: Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc. Natl Acad. Sci. USA 97(6), 2715-2718 (2000).
49. Koido S, Ohana M, Liu C et al.: Dendritic cells fused with human cancer cells: morphology, antigen expression and T cell stimulation. Clin. Immunol. 113(3), 261-269 (2004).
50. Homma S, Matai K, Irie M et al.: Immunotherapy using fusions of autologous dendritic cells and tumor cells showed effective clinical response in a patient with advanced gastric carcinoma. J. Gastroenterol. 38(10), 989-994 (2003). (Pubitemid 37455788)
51. Koido S, Hara E, Homma S et al.: Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Clin. Cancer Res. 11(21), 7891-7900 (2005).
52. Koido S, Homma S, Hara E et al.: In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells. J. Transl. Med. 61, 51(2008).
53. Benencia F, Courreges MC, Coukos G: Whole tumor antigen vaccination using dendritic cells: comparison of RNA electroporation and pulsing with UV-irradiated tumor cells. J. Transl. Med., 6, 21 (2008).
54. Parkhurst MR, DePan C, Riley JP, Rosenberg SA, Shu S: Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. J. Immunol. 170(10), 5317-5325 (2003). ■ Reports that tumor antigens are processed through the endogenous pathway of DC/tumor fusion cells in the context of MHC class I and class II molecules. (Pubitemid 36554767)
55. Koido S, Tanaka Y, Tajiri H, Gong J: Generation and functional assessment of antigen-specific T cells stimulated by fusion of dendritic cells and allogeneic breast cancer cells. Vaccine 25(14), 2610-2619 (2007). (Pubitemid 46400930)
56. Finn OJ: Cancer immunology. N. Engl. J. Med. 358(25), 2704-2715 (2008). ■ Very thorough review of how to develop cancer vaccines and the challenges.
57. Tanaka Y, Koido S, Ohana M, Liu C, Gong J: Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells. J. Immunol. 174, 1270-1280 (2005).
58. Toes RE, Ossendorp F, Offringa R, Melief CJ: CD4 T cells and their role in antitumor immune responses. J. Exp. Med. 189(5), 753-756 (1999).
59. + CTL in MHC class I-deficient mice through CD4 to CD8 conversion. J. Immunol. 172(12), 7848-7858 (2004).
60. Hurks HM, Metzelaar-Blok JA, Mulder A, Claas FH, Jager MJ: High frequency of allele-specific down-regulation of HLA class I expression in uveal melanoma cell lines. Int. J. Cancer. 85(5), 697-702 (2000).
61. + T-regulatory cells: toward therapy for human diseases. Immunol. Rev. 223, 391-421 (2008).
62. Fu J, Xu D, Liu Z et al.: Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 132(7), 2328-2339 (2007). (Pubitemid 46890865)
63. + T cells secreting interleukin-10 and transforming growth factor-β1 mediates suppression in the tumor microenvironment. Clin. Cancer Res. 13(15 Pt 1), 4345-4354 (2007).
64. Kosmaczewska A, Ciszak L, Potoczek S, Frydecka I: The significance of Treg cells in defective tumor immunity. Arch. Immunol. Ther. Exp. (Warsz), 56(3), 181-191 (2008).
65. Zhang M, Berndt BE, Chen JJ, Kao JY: Expression of a soluble TGF-β receptor by tumor cells enhances dendritic cell/tumor fusion vaccine efficacy. J. Immunol. 181(5), 3690-3697 (2008).
66. Pan PY, Wang GX, Yin B et al.: Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 111(1), 219-228 (2008).
67. Dannull J, Su Z, Rizzieri D et al.: Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115(12), 3623-3633 (2005).
68. Rutella S, Danese S, Leone G: Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 108(5), 1435-1440 (2006). (Pubitemid 44316106)
69. Vasir B, Wu Z, Crawford K et al.: Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells. J. Immunol. 181(1), 808-821 (2008).
70. de Gruijl TD, van den Eertwegh AJ, Pinedo HM, Scheper RJ: Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol. Immunother. 57(10), 1569-1577 (2008).
71. Fabre JW: The allogeneic response and tumor immunity. Nat. Med. 7(6), 649-652 (2001). ■ Very thorough review of allogeneic fusion-cell vaccine.
72. + T-cell immunity. J. Immunother. 29(5), 545-557 (2006).
73. Salcedo M, Bercovici N, Taylor R et al.: Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol. Immunother. 55(7), 819-829 (2006).
74. Bercovici N, Haicheur N, Massicard S et al.: Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. J. Immunother. 31(1), 101-112 (2008). (Pubitemid 351619409)
75. von Euw EM, Barrio MM, Furman D et al.: A Phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression. J. Transl. Med., 6, 6 (2008).
76. Satthaporn S, Robins A, Vassanasiri W et al.: Dendritic cells are dysfunctional in patients with operable breast cancer. Cancer Immunol. Immunother. 53(6), 510-518 (2004).
77. Avigan DE, Vasir B, George DJ et al.: Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J. Immunother. 30(7), 749-761 (2007). (Pubitemid 47480758)
78. Kikuchi T, Akasaki Y, Irie M et al.: Results of a Phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol. Immunother. 50(7), 337-344 (2001).
79. Kikuchi T, Akasaki Y, Abe T et al.: Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J. Immunother. 2004(27), 452-459 (2004). ■ Results of the first clinical trial of fusion-cell vaccine and IL-12. The vaccine is safe and partial responses was observed in glioma. (Pubitemid 39447353)
80. Avigan D, Vasir B, Gong J et al.: Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin. Cancer Res. 10(14), 4699-4708 (2004). ■ Reports the results of the clinical trial of fusion-cell vaccine with breast and renal cancer. The vaccine is safe and partial responses was observed in the patients.
81. Homma S, Kikuchi T, Ishiji N et al.: Cancer immunotherapy by fusion of dendritic and tumor cells and rh-IL-12. Eur. J. Clin. Invest. 35(4), 279-286 (2005).
82. Homma S, Sagawa Y, Ito M, Ohno T, Toda G: Cancer immunotherapy using dendritic/tumor-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses. Clin. Exp. Immunol. 144(1), 41-47 (2006).
83. Ogawa F, IInuma H, Okinaga K: Dendritic cell vaccine therapy by immunization with fusion cells of interleukin-2 gene-transduced, spleen-derived dendritic cells and tumour cells. Scand. J. Immunol. 59(5), 432-439 (2004).
84. Iinuma T, Homma S, Noda T et al.: Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine. J. Clin. Invest. 113(9), 1307-1317 (2004).
85. Iinuma H, Okinaga K, Fukushima R et al.: Superior protective and therapeutic effects of IL-12 and IL-18 gene-transduced dendritic neuroblastoma fusion cells on liver metastasis of murine neuroblastoma. J. Immunol. 176(6), 3461-3469 (2006). (Pubitemid 43363993)
86. Zheng R, Cohen PA, Paustian CA et al.: Paired Toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12. Cancer Res. 68(11), 4045-4049 (2008).
87. Celis E: Toll-like receptor ligands energize peptide vaccines through multiple paths. Cancer Res. 67(17), 7945-7947 (2007).
88. Wang RF: Functional control of regulatory T cells and cancer immunotherapy. Semin. Cancer Biol. 16(2), 106-114 (2006).
89. Wang RF: Regulatory T cells and Toll-like receptors in cancer therapy. Cancer Res. 66(10), 4987-4990 (2006).
90. Okamoto M, Oshikawa T, Tano T et al.: Involvement of Toll-like receptor 4 signaling in interferon-γ production and antitumor effect by streptococcal agent OK-432. J. Natl Cancer Inst. 95(4), 316-326 (2003). (Pubitemid 36336482)
91. Okamoto M, Furuichi S, Nishioka Y et al.: Expression of Toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with active component of OK-432, a streptococcal preparation. Cancer Res. 64(15), 5461-5470 (2004). (Pubitemid 39006570)
92. Shitara K, Ichimura O, Mitsuno T, Osawa T: Natural killer (NK) cell activating factor released from murine thymocytes stimulated with an anti-tumor streptococcal preparation, OK-432. J. Immunol. 134(2), 1039-1047 (1985).
93. Koido S, Hara E, Homma S et al.: Streptococcal preparation OK-432 promotes fusion efficiency and enhances induction of antigen-specific CTL by fusions of dendritic cells and colorectal cancer cells. J. Immunol. 178(1), 613-622 (2007). (Pubitemid 46033645)
94. Kuroki H, Morisaki M, Matsumoto K et al.: Streptococcal preparation OK-432: a new maturation factor of monocyte-derived dendritic cells for clinical use. Cancer Immunol. Immunother. 52(9), 561-568 (2003).
95. Misaki T, Watanabe Y, IIda Y et al.: Recruitment of T lymphocytes and induction of tumor necrosisi factor in thyroid cancer by a local immunotherapy. Cancer Immunol. Immunother. 35(2), 92-96 (1992).
96. Nakahara S, Tsunoda T, Baba T, Asabe S, Tahara H: Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Res. 63(14), 4112-4118 (2003). (Pubitemid 36917935)
97. Itoh T, Ueda Y, Okugawa K et al.: Streptococcal preparation OK 432 promote functional maturation of human monocyte-derived dendritic cells. Cancer Immunol. Immunother. 52(4), 207-214 (2003).
98. Yamanaka R, Homma J, Yajima N et al.: Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical Phase I/II trial. Clin. Cancer Res. 11(11), 4160-4167 (2005).
99. Ono T, Harada M, Yamada A et al.: Antitumor effects of systemic and local immunization with a CTL-directed peptide in combination with a local injection of OK-432. Clin. Cancer Res. 12(4), 1325-1332 (2006).
100. Lindquist S, Craig EA: The heat-shock proteins. Annu. Rev. Genet. 22, 631-677 (1988).
101. Srivastava PK: Immunotherapy for human cancer using heat shock protein-peptide complexes. Curr. Oncol. Rep. 7(2), 104-108 (2005).
102. Lee KP, Raez LE, Podack ER: Heat shock protein-based cancer vaccines. Hematol. Oncol. Clin. North Am. 20(3), 637-659 (2006).
103. Calderwood SK, Theriault JR, Gong J: How is the immune response affected by hyperthermia and heat shock proteins? Int. J. Hyperthermia. 21(8), 713-716 (2005).
104. Murshid A, Gong J, Calderwood SK: Heat-shock proteins in cancer vaccines: agents of antigen cross-presentation. Expert Rev. Vaccines 7(7), 1019-1030 (2008).
105. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK: Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278(5335), 117-120 (1999).
106. Georgopoulos C, Welch EA: Role of the major heat shock proteins as moleular chaperones. Annu. Rev. Cell Biol. 9, 601-634 (1993).
107. Milani V, Noessner E, Ghose S et al.: Heat shock protein 70: role in antigen presentation and immune stimulation. Int. J. Hyperthermia 18(6), 563-575 (2002). (Pubitemid 35469188)
108. + T cell cross-priming via transfer of proteasome substrates. Science 304(5675), 1318-1321 (2004).
109. Koido S, Hara E, Homma S et al.: Synergistic induction of antigen-specific CTL by fusions of TLR-stimulated dendritic cells and heat-stressed tumor cells. J. Immunol. 179(4), 4874-4883 (2007).
110. Trefzer U, Weingart G, Chen Y et al.: Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma. Int. J. Cancer. 85(5), 618-626 (2000). ■ First reports clinical responses of melanoma patients with fusion-cell vaccine.
111. Trefzer U, Herberth G, Wohlan K et al.: Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results. Vaccine 23(17-18), 2367-2373 (2005). (Pubitemid 40341486)
112. Krause SW, Neumann C, Soruri A et al.: The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. J. Immunother. 25(5), 421-428 (2002).
113. Holmes LM, Li J, Sticca RP, Wagner TE, Wei Y: A rapid, novel strategy to induce tumor cell-specific cytotoxic T lymphocyte responses using instant dentritomas. J. Immunother. 24(2), 122-129 (2001) (Pubitemid 32183058)
114. Weiner LM: Cancer immunotherapy - the endgame begins. N. Engl. J. Med. 358(25), 2664-2665 (2008). ■ Very thorough review of cancer vaccines.
115. Fricke I, Mirza N, Dupont J et al.: Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin. Cancer Res. 13(16), 4840-4848 (2007).
116. Ibe S, Qin Z, Schuler T, Preiss S, Blankenstein T: Tumor rejection by disturbing tumor stroma cell interactions. J. Exp. Med. 194(11), 1549-1559 (2001).
117. Schuler T, Kornig S, Blankenstein T: Tumor rejection by modulation of tumor stromal fibroblasts. J. Exp. Med. 198(10), 1487-1493 (2003).
118. Ko E, Luo W, Peng L, Wang X, Ferrone S: Mouse dendritic-endothelial cell hybrids and 4-1BB costimulation elicit antitumor effects mediated by broad antiangiogenic immunity. Cancer Res. 67(16), 7875-7884 (2007). (Pubitemid 47281383)
119. + T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells. Immunology 101(3), 316-324 (2000).
120. Savai R, Schermuly RT, Pullamsetti SS et al.: A combination hybrid-based vaccination/adoptive cellular therapy to prevent tumor growth by involvement of T cells. Cancer Res. 67(11), 5443-5453 (2007). (Pubitemid 46997285)
121. Dudley ME, Wunderlich JR, Yang JC et al.: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23(10), 2346-2357 (2005).
122. Morse MA, Hobeika AC, Osada T et al.: Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 112(3), 610-618 (2008).
123. Lake RA, Robinson BW: Immunotherapy and chemotherapy - a practical partnership. Nat. Rev. Cancer 5(5), 397-405 (2005). ■■ Very thorough analysis of the challenges facing cancer vaccines.
124. Nowak AK, Lake RA, Robinson BW: Combined chemoimmunotherapy of solid tumours: improving vaccines? Adv. Drug Deliv. Rev. 58(8), 975-990 (2006).